Evidence map›Paper›PMID 28582460›Full record

Trial reportPloS one2017

Admixture mapping of pelvic organ prolapse in African Americans from the Women's Health Initiative Hormone Therapy trial.

Ayush Giri, Katherine E Hartmann, Melinda C Aldrich, Renee M Ward, Jennifer M Wu, Amy J Park, Mariaelisa Graff, Lihong Qi, Rami Nassir, Robert B Wallace and 4 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Ayush GiriVanderbilt Epidemiology Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.ORCID http://orcid.org/0000-0002-7786-4670
Katherine E HartmannVanderbilt Epidemiology Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Melinda C AldrichDivision of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Renee M WardDepartment of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Jennifer M WuDepartment of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Amy J ParkDepartment of Obstetrics and Gynecology, Georgetown University School of Medicine, Washington, District of Columbia, United States of America.
Mariaelisa GraffDepartment of Epidemiology, Gillings School of Global Public health, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Lihong QiDivision of Biostatistics, Department of Public Health Sciences, School of Medicine, University of California, Davis, Davis, California, United States of America.
Rami NassirDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Davis, California, United States of America.
Robert B WallaceDepartment of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa, United States of America.
Mary J O'SullivanDepartment of Obstetrics and Gynecology, Miller School of Medicine, Miami, Florida, United States of America.
Kari E NorthDepartment of Epidemiology, Gillings School of Global Public health, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Digna R Velez EdwardsVanderbilt Epidemiology Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Todd L EdwardsDivision of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Vanderbilt University Medical Center · USUniversity of North Carolina at Chapel Hill · USUniversity of California, Davis · USGeorgetown University · USUniversity of Iowa · USUniversity of Miami · US

Funding

VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
WOMENS HEALTH INITIATIVE-N01WH22110N01WH022110 · WH · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSS, PRENTICE · 1992 to 2006
$1.2M
Unraveling Genetic Determinants of Lung Cancer Risk in African AmericansK07CA172294 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALDRICH, MELINDA · 2013 to 2017
$801k
Translational Research in Pelvic Floor DisordersK23HD068404 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WU, JENNIFER M. · 2011 to 2014
$509k
NCI NIH HHS K07 CA172294NCRR NIH HHS UL1 RR024975NHLBI NIH HHS N02 HL064278NICHD NIH HHS K23 HD068404WHI NIH HHS N01 WH022110
6 · The paper itself

Abstract

Evidence suggests European American (EA) women have two- to five-fold increased odds of having pelvic organ prolapse (POP) when compared with African American (AA) women. However, the role of genetic ancestry in relation to POP risk is not clear. Here we evaluate the association between genetic ancestry and POP in AA women from the Women's Health Initiative Hormone Therapy trial. Women with grade 1 or higher classification, and grade 2 or higher classification for uterine prolapse, cystocele or rectocele at baseline or during follow-up were considered to have any POP (N = 805) and moderate/severe POP (N = 156), respectively. Women with at least two pelvic exams with no indication for POP served as controls (N = 344). We performed case-only, and case-control admixture-mapping analyses using multiple logistic regression while adjusting for age, BMI, parity and global ancestry. We evaluated the association between global ancestry and POP using multiple logistic regression. European ancestry at the individual level was not associated with POP risk. Case-only and case-control local ancestry analyses identified two ancestry-specific loci that may be associated with POP. One locus (Chromosome 15q26.2) achieved empirically-estimated statistical significance and was associated with decreased POP odds (considering grade ≥2 POP) with each unit increase in European ancestry (OR: 0.35; 95% CI: 0.30, 0.57; p-value = 1.48x10-5). This region includes RGMA, a potent regulator of the BMP family of genes. The second locus (Chromosome 1q42.1-q42.3) was associated with increased POP odds with each unit increase in European ancestry (Odds ratio [OR]: 1.69; 95% confidence interval [CI]: 1.28, 2.22; p-value = 1.93x10-4). Although this region did not reach statistical significance after considering multiple comparisons, it includes potentially relevant genes including TBCE, and ACTA1. Unique non-overlapping European and African ancestry-specific susceptibility loci may be associated with increased POP risk.

Indexed as

Quantitative Trait, HeritableQuantitative Trait LociActinsAgedBlack or African AmericanBody Mass IndexCase-Control StudiesCystoceleFemaleGene ExpressionGPI-Linked ProteinsHumansLogistic ModelsMiddle AgedMolecular ChaperonesNerve Tissue ProteinsActinsGPI-Linked ProteinsMolecular ChaperonesNerve Tissue ProteinsRGMA protein, humanTBCE protein, human

Identifiers

PMID28582460
PMCPMC5459562
OpenAlexW2622094125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.